This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
AMAG Pharmaceuticals Inc
AMAG : NASDAQ : Health Care
$42.12 | %
Today's Range: 38.03 - 42.15
Avg. Daily Volume: 1,008,400
10/02/15 - 3:59 PM ET

Financial Analysis

AMAG PHARMACEUTICALS INC's gross profit margin for the second quarter of its fiscal year 2015 has increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. AMAG PHARMACEUTICALS INC has average liquidity. Currently, the Quick Ratio is 1.43 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 269.44% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q2 FY15 Q2 FY14
Net Sales ($mil)123.8824.8
EBITDA ($mil)86.131.84
EBIT ($mil)66.281.62
Net Income ($mil)33.26-1.55

Balance Sheet Q2 FY15 Q2 FY14
Cash & Equiv. ($mil)398.41386.47
Total Assets ($mil)1639.28448.85
Total Debt ($mil)483.2164.13
Equity ($mil)712.98192.99

Profitability Q2 FY15 Q2 FY14
Gross Profit Margin98.5481.22
EBITDA Margin69.527.42
Operating Margin53.56.55
Sales Turnover0.180.2
Return on Assets11.62-2.77
Return on Equity26.73-6.45
Debt Q2 FY15 Q2 FY14
Current Ratio1.7111.4
Interest Expense10.213.05
Interest Coverage6.490.53

Share Data Q2 FY15 Q2 FY14
Shares outstanding (mil)30.8721.96
Div / share0.00.0
Book value / share23.18.79
Institutional Own % n/a n/a
Avg Daily Volume973403.0739985.0


BUY. AMAG PHARMACEUTICALS INC's P/E ratio indicates a significant discount compared to an average of 112.80 for the Biotechnology industry and a significant discount compared to the S&P 500 average of 19.47. To use another comparison, its price-to-book ratio of 2.07 indicates a discount versus the S&P 500 average of 2.59 and a significant discount versus the industry average of 18.51. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, AMAG PHARMACEUTICALS INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
AMAG 8.03 Peers 112.80   AMAG 14.75 Peers 38.44

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

AMAG is trading at a significant discount to its peers.


Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

AMAG is trading at a significant discount to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
AMAG 6.22 Peers 20.07   AMAG NM Peers 0.60

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

AMAG is trading at a significant discount to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

AMAG's negative PEG ratio makes this valuation measure meaningless.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
AMAG 2.07 Peers 18.51   AMAG 1124.13 Peers 34.59

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

AMAG is trading at a significant discount to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

AMAG is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
AMAG 5.04 Peers 337.50   AMAG 228.37 Peers 92.43

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

AMAG is trading at a significant discount to its industry on this measurement.


Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

AMAG has a sales growth rate that significantly exceeds its peers.



Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums

Latest Stock Upgrades/Downgrades

Top Rated Stocks Top Rated Funds Top Rated ETFs